SCHEMBL18602017

SCHEMBL18602017

CC(C)(C)OC(=O)c1ccccc1CN1CN(c2ccccc2)C2(CCN(CCCN3C(=O)C(C)(C)c4ccccc43)CC2)O1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
NFKB1 P19838 1/20 0.37
THPO P40225 1/20 0.37
HIF1A Q16665 1/20 0.37
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
GMNN O75496 1/20 0.36
MAPK1 P28482 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36
KMT2A Q03164 1/20 0.36
CCR5 P51681 2/20 0.34
OPRL1 P41146 2/20 0.34
CYP1A2 P05177 1/20 0.33
TSHR P16473 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA1A P35348 1/20 0.33
DRD2 P14416 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18601796 0.93 OPRL1 (0.40) CCR5OPRL1
SCHEMBL319062 0.85 OPRL1 (0.42) CYP3A4CYP2D6MEN1MAPK1KMT2A
SCHEMBL318109 0.80 CYP3A4 (0.44) CYP3A4CYP2D6CYP2C9NFKB1THPO
SCHEMBL318382 0.79 MEN1 (0.42) CYP3A4CYP2D6MEN1MAPK1KMT2A
SCHEMBL319212 0.78 OPRL1 (0.42) CYP3A4CYP2D6MEN1MAPK1KMT2A
SCHEMBL318814 0.75 MEN1 (0.48) CYP3A4CYP2D6MEN1MAPK1KMT2A
SCHEMBL319039 0.75 MEN1 (0.45) CYP3A4CYP2D6MEN1MAPK1KMT2A
SCHEMBL319185 0.74 MEN1 (0.43) CYP3A4CYP2D6MEN1MAPK1KMT2A
SCHEMBL319835 0.74 MEN1 (0.51) CYP3A4CYP2D6CYP2C9MEN1MAPK1
SCHEMBL318809 0.73 MEN1 (0.44) CYP3A4CYP2D6MEN1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3138841-A1 D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE Altos Therapeutics, LLC (US) 2017-03-08 EP disclosed